Biocomposites announced today that the company’s unique bone graft substitute geneX, has been cleared for use by the State Food and Drug Administration (SFDA) of the People’s Republic of China.
geneX is a synthetic bone graft material with a unique bi-phasic composition manufactured through a proprietary process that confers the product with a reproducible negative surface charge. This property stimulates bone cell activity, accelerating bone formation and fusion by harnessing key proteins and directing osteoblast adhesion and proliferation for rapid osteogenesis. geneX is fully resorbable and is completely replaced by bone.
Commenting on the clearance, Dr Simon Zhou, General Manager of Biocomposites (Shanghai) Ltd said ” In the fast growing Chinese market, surgeons and patients can now take full advantage of the significant benefits that geneX brings over traditional bone graft substitutes “.